Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study

Julian P. Halcox, José R. Banegas, Carine Roy, Jean Dallongeville, Guy De Backer, Eliseo Guallar, Joep Perk, David Hajage, Karin M. Henriksson, Claudio Borghi

Research output: Contribution to journalArticle

Abstract

Background: Atherogenic dyslipidemia is associated with poor cardiovascular outcomes, yet markers of this condition are often ignored in clinical practice. Here, we address a clear evidence gap by assessing the prevalence and treatment of two markers of atherogenic dyslipidemia: elevated triglyceride levels and low levels of highdensity lipoprotein cholesterol. Methods: This cross-sectional observational study assessed the prevalence of two atherogenic dyslipidemia markers, high triglyceride levels and low high-density lipoprotein cholesterol levels, in the study population from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA; N = 7641; of whom 51.6% were female and 95.6% were White/Caucasian). The EURIKA population included European patients, aged at least 50 years with at least one cardiovascular risk factor but no history of cardiovascular disease. Results: Over 20% of patients from the EURIKA population have either triglyceride or high-density lipoprotein cholesterol levels characteristic of atherogenic dyslipidemia. Furthermore, the proportions of patients with one of these markers were higher in subpopulations with type 2 diabetes mellitus or those already calculated to be at high risk of cardiovascular disease. Approximately 55% of the EURIKA population who have markers of atherogenic dyslipidemia are not receiving lipid-lowering therapy. Conclusions: A considerable proportion of patients with at least one major cardiovascular risk factor in the primary cardiovascular disease prevention setting have markers of atherogenic dyslipidemia. The majority of these patients are not receiving optimal treatment, as specified in international guidelines, and thus their risk of developing cardiovascular disease is possibly underestimated.

Original languageEnglish (US)
Article number160
JournalBMC Cardiovascular Disorders
Volume17
Issue number1
DOIs
StatePublished - 2017

Fingerprint

Primary Prevention
Dyslipidemias
Observational Studies
Cardiovascular Diseases
Cross-Sectional Studies
Triglycerides
HDL Cholesterol
Population
Therapeutics
Risk Management
LDL Cholesterol
Type 2 Diabetes Mellitus
Guidelines
Lipids

Keywords

  • Atherogenic dyslipidemia
  • Cardiovascular disease
  • Epidemiology
  • Risk factors/global assessment

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe : EURIKA, a cross-sectional observational study. / Halcox, Julian P.; Banegas, José R.; Roy, Carine; Dallongeville, Jean; De Backer, Guy; Guallar, Eliseo; Perk, Joep; Hajage, David; Henriksson, Karin M.; Borghi, Claudio.

In: BMC Cardiovascular Disorders, Vol. 17, No. 1, 160, 2017.

Research output: Contribution to journalArticle

Halcox, Julian P. ; Banegas, José R. ; Roy, Carine ; Dallongeville, Jean ; De Backer, Guy ; Guallar, Eliseo ; Perk, Joep ; Hajage, David ; Henriksson, Karin M. ; Borghi, Claudio. / Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe : EURIKA, a cross-sectional observational study. In: BMC Cardiovascular Disorders. 2017 ; Vol. 17, No. 1.
@article{6b81e092a6024ab784638fe46a1a0005,
title = "Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study",
abstract = "Background: Atherogenic dyslipidemia is associated with poor cardiovascular outcomes, yet markers of this condition are often ignored in clinical practice. Here, we address a clear evidence gap by assessing the prevalence and treatment of two markers of atherogenic dyslipidemia: elevated triglyceride levels and low levels of highdensity lipoprotein cholesterol. Methods: This cross-sectional observational study assessed the prevalence of two atherogenic dyslipidemia markers, high triglyceride levels and low high-density lipoprotein cholesterol levels, in the study population from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA; N = 7641; of whom 51.6{\%} were female and 95.6{\%} were White/Caucasian). The EURIKA population included European patients, aged at least 50 years with at least one cardiovascular risk factor but no history of cardiovascular disease. Results: Over 20{\%} of patients from the EURIKA population have either triglyceride or high-density lipoprotein cholesterol levels characteristic of atherogenic dyslipidemia. Furthermore, the proportions of patients with one of these markers were higher in subpopulations with type 2 diabetes mellitus or those already calculated to be at high risk of cardiovascular disease. Approximately 55{\%} of the EURIKA population who have markers of atherogenic dyslipidemia are not receiving lipid-lowering therapy. Conclusions: A considerable proportion of patients with at least one major cardiovascular risk factor in the primary cardiovascular disease prevention setting have markers of atherogenic dyslipidemia. The majority of these patients are not receiving optimal treatment, as specified in international guidelines, and thus their risk of developing cardiovascular disease is possibly underestimated.",
keywords = "Atherogenic dyslipidemia, Cardiovascular disease, Epidemiology, Risk factors/global assessment",
author = "Halcox, {Julian P.} and Banegas, {Jos{\'e} R.} and Carine Roy and Jean Dallongeville and {De Backer}, Guy and Eliseo Guallar and Joep Perk and David Hajage and Henriksson, {Karin M.} and Claudio Borghi",
year = "2017",
doi = "10.1186/s12872-017-0591-5",
language = "English (US)",
volume = "17",
journal = "BMC Cardiovascular Disorders",
issn = "1471-2261",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe

T2 - EURIKA, a cross-sectional observational study

AU - Halcox, Julian P.

AU - Banegas, José R.

AU - Roy, Carine

AU - Dallongeville, Jean

AU - De Backer, Guy

AU - Guallar, Eliseo

AU - Perk, Joep

AU - Hajage, David

AU - Henriksson, Karin M.

AU - Borghi, Claudio

PY - 2017

Y1 - 2017

N2 - Background: Atherogenic dyslipidemia is associated with poor cardiovascular outcomes, yet markers of this condition are often ignored in clinical practice. Here, we address a clear evidence gap by assessing the prevalence and treatment of two markers of atherogenic dyslipidemia: elevated triglyceride levels and low levels of highdensity lipoprotein cholesterol. Methods: This cross-sectional observational study assessed the prevalence of two atherogenic dyslipidemia markers, high triglyceride levels and low high-density lipoprotein cholesterol levels, in the study population from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA; N = 7641; of whom 51.6% were female and 95.6% were White/Caucasian). The EURIKA population included European patients, aged at least 50 years with at least one cardiovascular risk factor but no history of cardiovascular disease. Results: Over 20% of patients from the EURIKA population have either triglyceride or high-density lipoprotein cholesterol levels characteristic of atherogenic dyslipidemia. Furthermore, the proportions of patients with one of these markers were higher in subpopulations with type 2 diabetes mellitus or those already calculated to be at high risk of cardiovascular disease. Approximately 55% of the EURIKA population who have markers of atherogenic dyslipidemia are not receiving lipid-lowering therapy. Conclusions: A considerable proportion of patients with at least one major cardiovascular risk factor in the primary cardiovascular disease prevention setting have markers of atherogenic dyslipidemia. The majority of these patients are not receiving optimal treatment, as specified in international guidelines, and thus their risk of developing cardiovascular disease is possibly underestimated.

AB - Background: Atherogenic dyslipidemia is associated with poor cardiovascular outcomes, yet markers of this condition are often ignored in clinical practice. Here, we address a clear evidence gap by assessing the prevalence and treatment of two markers of atherogenic dyslipidemia: elevated triglyceride levels and low levels of highdensity lipoprotein cholesterol. Methods: This cross-sectional observational study assessed the prevalence of two atherogenic dyslipidemia markers, high triglyceride levels and low high-density lipoprotein cholesterol levels, in the study population from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA; N = 7641; of whom 51.6% were female and 95.6% were White/Caucasian). The EURIKA population included European patients, aged at least 50 years with at least one cardiovascular risk factor but no history of cardiovascular disease. Results: Over 20% of patients from the EURIKA population have either triglyceride or high-density lipoprotein cholesterol levels characteristic of atherogenic dyslipidemia. Furthermore, the proportions of patients with one of these markers were higher in subpopulations with type 2 diabetes mellitus or those already calculated to be at high risk of cardiovascular disease. Approximately 55% of the EURIKA population who have markers of atherogenic dyslipidemia are not receiving lipid-lowering therapy. Conclusions: A considerable proportion of patients with at least one major cardiovascular risk factor in the primary cardiovascular disease prevention setting have markers of atherogenic dyslipidemia. The majority of these patients are not receiving optimal treatment, as specified in international guidelines, and thus their risk of developing cardiovascular disease is possibly underestimated.

KW - Atherogenic dyslipidemia

KW - Cardiovascular disease

KW - Epidemiology

KW - Risk factors/global assessment

UR - http://www.scopus.com/inward/record.url?scp=85027560648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027560648&partnerID=8YFLogxK

U2 - 10.1186/s12872-017-0591-5

DO - 10.1186/s12872-017-0591-5

M3 - Article

C2 - 28623902

AN - SCOPUS:85027560648

VL - 17

JO - BMC Cardiovascular Disorders

JF - BMC Cardiovascular Disorders

SN - 1471-2261

IS - 1

M1 - 160

ER -